Short Interest in Mainz Biomed (NASDAQ:MYNZ) Increases By 190.6%

Mainz Biomed (NASDAQ:MYNZ) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 101,700 shares, a growth of 190.6% from the January 31st total of 35,000 shares. Based on an average daily trading volume, of 203,700 shares, the short-interest ratio is presently 0.5 days. Currently, 5.4% of the company’s stock are sold short.

Mainz Biomed Price Performance

NASDAQ MYNZ opened at $6.04 on Friday. Mainz Biomed has a 1 year low of $3.65 and a 1 year high of $45.60. The company has a market cap of $12.09 million, a price-to-earnings ratio of -0.09 and a beta of 0.32. The stock’s fifty day moving average price is $5.38 and its 200 day moving average price is $8.81.

Institutional Investors Weigh In On Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC purchased a new stake in shares of Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed at the end of the most recent quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on MYNZ. HC Wainwright cut Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th. Maxim Group initiated coverage on shares of Mainz Biomed in a research report on Friday, February 14th. They issued a “buy” rating and a $14.00 price objective for the company.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.